Zealand Pharma

Share Issue/Capital Change • Feb 23, 2012

Copenhagen, 2012-02-23 11:53 CET (GLOBE NEWSWIRE) -- Company Announcement

No. 5/2012

Copenhagen, 23 February 2012 - Following Company Announcement no. 4/2012 of 10
February 2012, Zealand Pharma (ZEAL.CO) hereby announces that the final number
of warrants issued by the company’s Board of Directors at the board meeting of
10 February 2012, according to the authority provided by Section 8.1 of the
Articles of Association, amounts to 240,250 for the subscription of shares of
up to nominally DKK 240,250.

For a further description of the issued warrants, reference is made to Company
Announcement no. 4/2012.

The amendment of the Articles of Association entailed by the issue of warrants
has today been registered with the Danish Commerce and Companies Agency. The
new Articles of Association for Zealand Pharma are attached to this
announcement and are also available on the company’s website;
www.zealandpharma.com.

For further information, please contact:

Hanne Leth Hillman, Vice President for IR & Corporate Communication,

Tel: +45 5060 3689, hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company
based in Copenhagen, Denmark with a mature clinical pipeline of innovative
peptide based drugs. The company's lead product is lixisenatide (Lyxumia® 1)),
a once-daily GLP-1 agonist for the treatment of Type 2 diabetes, invented by
Zealand Pharma and licensed to Sanofi. In November, Sanofi submitted a
marketing authorization application (MAA) for lixisenatide in Europe and
submission for regulatory approval in the United States is expected in Q4 2012.
Zealand Pharma also has a collaboration with Boehringer Ingelheim covering dual
acting glucagon/GLP-1 agonists, including ZP2929, for the treatment of diabetes
and obesity, and a license agreement with Helsinn Healthcare on elsiglutide, a
clinical stage GLP-2 drug for the treatment of chemotherapy-induced diarrhea.

Zealand Pharma specializes in the discovery, optimization and development of
novel peptide drugs, and all drug candidates in its pipeline have been
identified through the company's own drug discovery activities. Zealand
Pharma's products target disease areas where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high.

For further information: www.zealandpharma.com.

Note 1) Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is
not currently approved or licensed anywhere in the world.